本帖最后由 老马 于 2012-1-13 21:20 编辑 * m- Z! @. ?! i4 D& x1 F
+ e$ o2 k. J) s0 E爱必妥和阿瓦斯丁的比较
8 o+ r: h5 X$ `$ }' d" `: ~: i( G
7 i4 r4 u W# H0 Qhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/' O- M6 o) B' O( f! x
) H) G0 x9 y) w. F3 @7 v" l
+ M0 U# _& O# S. P; B1 a3 n3 `
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
|! ^: q# ~% u8 T; H2 A==================================================: m& r( V: n2 f; a& C" h$ n
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). q" y4 q6 a! A
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" D' f+ p/ ]0 s! c uResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ g' z( u: ~$ g0 I0 h& q6 r
|